169545-27-1

中文名称 N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN

英文名称 IRL-2500

CAS 169545-27-1

分子式 C36H35N3O4

分子量 573.68

MOL 文件 169545-27-1.mol

更新日期 2025/05/07 21:35:40

169545-27-1 结构式

基本信息物理化学性质安全数据图谱信息 N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN价格(试剂级) 常见问题列表

基本信息

中文别名

T15596
化合物 T15596
化合物IRL 2500
(S)-2-((R)-3-([1,1'-联苯]-4-基)-2-(N,3,5-三甲基苯甲酰胺基)丙酰胺基)-3-(1H-吲哚-3-基)丙酸

英文别名

IRL-2500
L-Tryptophan, 3-[1,1'-biphenyl]-4-yl-N-(3,5-dimethylbenzoyl)-N-methyl-D-alanyl-
N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN

物理化学性质

沸点893.7±65.0 °C(Predicted)

密度1.246±0.06 g/cm3(Predicted)

储存条件Keep in dark place,Sealed in dry,Store in freezer, under -20°C

溶解度Soluble to 100 mM in 1eq. NaOH

酸度系数(pKa)3.34±0.10(Predicted)

形态粉末

颜色White to light yellow

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS07

警示词警告

危险性描述H302-H315-H319-H335

防范说明P261-P305+P351+P338

图谱信息

N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN(169545-27-1)核磁图(¹HNMR)

N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/02/08	HY-103460	N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN IRL 2500	169545-27-1	1 mg	448元
2025/02/08	HY-103460	N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN IRL 2500	169545-27-1	5mg	1215元
2025/02/08	HY-103460	N-3-[1,1'-BIPHENYL]-4-YL-N-(3,5-DIMETHYLBENZOYL)-N-METHYL-D-ALANYL-L-TRYPTOPHAN IRL 2500	169545-27-1	10 mM * 1 mLin DMSO	1533元

常见问题列表

生物活性

IRL 2500 是一种有效的内皮素受体 (Endothelin receptor) 拮抗剂，其 ETB 和 ETA 受体的 IC50 值分别为 1.3 和 94 nM。 IRL 2500 在体内抑制 ETB 受体介导的血压升高和肾血管阻力。

靶点

ET _B

1.3 nM (IC ₅₀ )

ET _A

94 nM (IC ₅₀ )

体内研究

IRL 2500 (intravenous injection;10 mg/kg) inhibits the initial transient decrease in mean arterial pressure (MAP) induced by the ETB-selective agonist IRL 1620 in rats, IRL 2500 also attenuates the IRL 1620-mediated increase in renal vascular resistance (RVR) in the anesthetized rat. IRL 2500 (intravenous injection;10 mg/kg) pre-reatment significantly reduces the initial vasodepressor response to endothelin-1 (ET-1) and IRL 1620, however, it is not alters the secondary and sustained pressor response to these agonists.